Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04947683
What this trial is testing

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Latin American Cooperative Oncology Group 101
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Early research (Phase 1)Ended earlyNCT02511184
What this trial is testing

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Who this might be right for
ALK-positive Advanced NSCLC
Pfizer 9
Large-scale testing (Phase 3)Looking for participantsNCT06627647
What this trial is testing

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
AstraZeneca 1,160
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)WithdrawnNCT03164694
What this trial is testing

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Study completedNCT01871805
What this trial is testing

Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 134
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Not applicableEnrolling By InvitationNCT06846736
What this trial is testing

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

Who this might be right for
Alk-positive Non-Small Cell Lung CancerALK-inhibitor Treated
Sheba Medical Center 200
Not applicableUnknownNCT05132218
What this trial is testing

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Peking University Cancer Hospital & Institute 180
Testing effectiveness (Phase 2)Study completedNCT01562015
What this trial is testing

Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Synta Pharmaceuticals Corp. 12
Testing effectiveness (Phase 2)Study completedNCT01625234
What this trial is testing

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Xcovery Holdings, Inc. 131
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Testing effectiveness (Phase 2)Study completedNCT01970865
What this trial is testing

PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Who this might be right for
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Pfizer 364
Not applicableLooking for participantsNCT05599412
What this trial is testing

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Who this might be right for
Metastatic ALK+ Non Small Cell Lung Cancer
Pfizer 600
Not applicableStudy completedNCT02171286
What this trial is testing

The Oncopanel Pilot (TOP) Study

Who this might be right for
Colorectal Cancer MetastaticAdvanced Non-Small Cell Lung CarcinomaAdvanced Melanoma+2 more
British Columbia Cancer Agency 432
Not applicableUnknownNCT02946216
What this trial is testing

ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer MetastaticAdenocarcinoma of Lung+1 more
First People's Hospital of Hangzhou 200
Not applicableAvailableNCT04146571
What this trial is testing

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK Gene Rearrangement Positive
Xcovery Holdings, Inc.
Testing effectiveness (Phase 2)UnknownNCT05361564
What this trial is testing

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 12
Post-approval studies (Phase 4)Not Yet RecruitingNCT07674368
What this trial is testing

Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

Who this might be right for
ALK Fusion-positive Non-small Cell Lung Cancer
Hunan Cancer Hospital 29
Next Page